vs

Side-by-side financial comparison of CRYO CELL INTERNATIONAL INC (CCEL) and Falcon's Beyond Global, Inc. (FBYD). Click either name above to swap in a different company.

CRYO CELL INTERNATIONAL INC is the larger business by last-quarter revenue ($7.8M vs $6.6M, roughly 1.2× Falcon's Beyond Global, Inc.). Falcon's Beyond Global, Inc. runs the higher net margin — -4.5% vs -48.7%, a 44.2% gap on every dollar of revenue. On growth, Falcon's Beyond Global, Inc. posted the faster year-over-year revenue change (383.5% vs -2.3%). CRYO CELL INTERNATIONAL INC produced more free cash flow last quarter ($1.2M vs $-4.3M). Over the past eight quarters, Falcon's Beyond Global, Inc.'s revenue compounded faster (108.4% CAGR vs -0.1%).

Cryo-Cell International, Inc. is a cord blood bank. It was founded by Dan Richard in 1989. Cryo-Cell International is the first private cord blood bank to separate and store stem cells. Cryo-Cell is headquartered outside of Tampa, in Oldsmar, Florida. In January 1997, the Company's stock began trading on the NASDAQ Small Cap market under symbol CCEL.

500 Global is an early-stage venture fund and seed accelerator founded in 2010 by Dave McClure and Christine Tsai. The fund admitted a first "class" of twelve startups to its incubator office in Mountain View, California in February 2011. They expanded to a second class of 21 in June 2011 and a third class of 34 in October 2011. 500 Global has $2.3 billion in assets under management (AUM) as of March 2024.

CCEL vs FBYD — Head-to-Head

Bigger by revenue
CCEL
CCEL
1.2× larger
CCEL
$7.8M
$6.6M
FBYD
Growing faster (revenue YoY)
FBYD
FBYD
+385.7% gap
FBYD
383.5%
-2.3%
CCEL
Higher net margin
FBYD
FBYD
44.2% more per $
FBYD
-4.5%
-48.7%
CCEL
More free cash flow
CCEL
CCEL
$5.6M more FCF
CCEL
$1.2M
$-4.3M
FBYD
Faster 2-yr revenue CAGR
FBYD
FBYD
Annualised
FBYD
108.4%
-0.1%
CCEL

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CCEL
CCEL
FBYD
FBYD
Revenue
$7.8M
$6.6M
Net Profit
$-3.8M
$-296.0K
Gross Margin
77.9%
Operating Margin
-50.6%
-30.9%
Net Margin
-48.7%
-4.5%
Revenue YoY
-2.3%
383.5%
Net Profit YoY
-105.1%
97.5%
EPS (diluted)
$-0.46
$-0.01

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CCEL
CCEL
FBYD
FBYD
Q4 25
$7.8M
$6.6M
Q3 25
$7.8M
$4.1M
Q2 25
$7.9M
$2.5M
Q1 25
$8.0M
$1.7M
Q4 24
$8.0M
$1.4M
Q3 24
$8.1M
$2.1M
Q2 24
$8.0M
$1.8M
Q1 24
$7.9M
$1.5M
Net Profit
CCEL
CCEL
FBYD
FBYD
Q4 25
$-3.8M
$-296.0K
Q3 25
$749.4K
$-10.4M
Q2 25
$355.8K
$25.1M
Q1 25
$282.9K
$-8.1M
Q4 24
$-1.9M
$-11.9M
Q3 24
$1.1M
$39.3M
Q2 24
$655.8K
$8.0M
Q1 24
$556.2K
$114.0M
Gross Margin
CCEL
CCEL
FBYD
FBYD
Q4 25
77.9%
Q3 25
77.0%
Q2 25
76.6%
Q1 25
75.1%
Q4 24
78.4%
Q3 24
73.6%
Q2 24
74.8%
Q1 24
73.7%
Operating Margin
CCEL
CCEL
FBYD
FBYD
Q4 25
-50.6%
-30.9%
Q3 25
24.3%
-90.9%
Q2 25
18.8%
-53.0%
Q1 25
13.3%
-371.1%
Q4 24
-1.5%
-335.6%
Q3 24
17.2%
-118.9%
Q2 24
17.3%
-195.9%
Q1 24
10.5%
-350.5%
Net Margin
CCEL
CCEL
FBYD
FBYD
Q4 25
-48.7%
-4.5%
Q3 25
9.6%
-256.8%
Q2 25
4.5%
985.2%
Q1 25
3.5%
-473.8%
Q4 24
-23.2%
-871.7%
Q3 24
13.0%
1899.5%
Q2 24
8.2%
446.5%
Q1 24
7.1%
7521.4%
EPS (diluted)
CCEL
CCEL
FBYD
FBYD
Q4 25
$-0.46
$-0.01
Q3 25
$0.09
$-0.13
Q2 25
$0.04
$0.30
Q1 25
$0.03
$-0.13
Q4 24
$-0.23
$-0.25
Q3 24
$0.13
$0.39
Q2 24
$0.08
$0.00
Q1 24
$0.07
$1.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CCEL
CCEL
FBYD
FBYD
Cash + ST InvestmentsLiquidity on hand
$3.3M
$1.9M
Total DebtLower is stronger
$8.4M
$15.6M
Stockholders' EquityBook value
$-18.6M
$11.9M
Total Assets
$61.7M
$66.7M
Debt / EquityLower = less leverage
1.31×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CCEL
CCEL
FBYD
FBYD
Q4 25
$3.3M
$1.9M
Q3 25
$3.2M
$4.3M
Q2 25
$4.4M
$26.1M
Q1 25
$3.5M
$1.1M
Q4 24
$3.5M
$825.0K
Q3 24
$2.1M
$828.0K
Q2 24
$1.5M
$1.7M
Q1 24
$979.6K
$1.1M
Total Debt
CCEL
CCEL
FBYD
FBYD
Q4 25
$8.4M
$15.6M
Q3 25
$8.4M
Q2 25
$8.4M
Q1 25
$8.5M
Q4 24
$8.5M
$41.2M
Q3 24
$8.5M
$10.3M
Q2 24
$8.5M
$15.7M
Q1 24
$8.6M
$15.1M
Stockholders' Equity
CCEL
CCEL
FBYD
FBYD
Q4 25
$-18.6M
$11.9M
Q3 25
$-14.8M
$9.2M
Q2 25
$-15.6M
$414.0K
Q1 25
$-14.7M
$-11.6M
Q4 24
$-13.2M
$-9.0M
Q3 24
$-9.6M
$-1.4M
Q2 24
$-10.7M
$-44.7M
Q1 24
$-10.3M
$-61.7M
Total Assets
CCEL
CCEL
FBYD
FBYD
Q4 25
$61.7M
$66.7M
Q3 25
$63.2M
$66.8M
Q2 25
$64.4M
$89.2M
Q1 25
$64.4M
$56.7M
Q4 24
$64.7M
$61.2M
Q3 24
$62.9M
$66.5M
Q2 24
$62.6M
$65.9M
Q1 24
$61.7M
$67.8M
Debt / Equity
CCEL
CCEL
FBYD
FBYD
Q4 25
1.31×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CCEL
CCEL
FBYD
FBYD
Operating Cash FlowLast quarter
$1.3M
$-4.3M
Free Cash FlowOCF − Capex
$1.2M
$-4.3M
FCF MarginFCF / Revenue
15.5%
-66.0%
Capex IntensityCapex / Revenue
0.9%
0.3%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$5.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CCEL
CCEL
FBYD
FBYD
Q4 25
$1.3M
$-4.3M
Q3 25
$2.5M
$-13.3M
Q2 25
$707.0K
$-7.9M
Q1 25
$954.1K
$945.0K
Q4 24
$2.2M
$-3.8M
Q3 24
$2.4M
$-2.4M
Q2 24
$1.8M
$-2.6M
Q1 24
$-356.9K
$-3.8M
Free Cash Flow
CCEL
CCEL
FBYD
FBYD
Q4 25
$1.2M
$-4.3M
Q3 25
$2.5M
$-13.4M
Q2 25
$644.6K
Q1 25
$892.0K
$853.0K
Q4 24
$2.1M
$-3.8M
Q3 24
$2.3M
$-2.4M
Q2 24
$21.5K
$-2.6M
Q1 24
$-814.6K
$-3.8M
FCF Margin
CCEL
CCEL
FBYD
FBYD
Q4 25
15.5%
-66.0%
Q3 25
31.9%
-329.6%
Q2 25
8.1%
Q1 25
11.2%
49.9%
Q4 24
26.8%
-278.7%
Q3 24
27.9%
-114.9%
Q2 24
0.3%
-145.6%
Q1 24
-10.4%
-248.8%
Capex Intensity
CCEL
CCEL
FBYD
FBYD
Q4 25
0.9%
0.3%
Q3 25
0.5%
1.0%
Q2 25
0.8%
0.0%
Q1 25
0.8%
5.4%
Q4 24
0.1%
0.1%
Q3 24
2.3%
0.2%
Q2 24
21.8%
0.1%
Q1 24
5.8%
0.3%
Cash Conversion
CCEL
CCEL
FBYD
FBYD
Q4 25
Q3 25
3.38×
Q2 25
1.99×
-0.31×
Q1 25
3.37×
Q4 24
Q3 24
2.32×
-0.06×
Q2 24
2.70×
-0.33×
Q1 24
-0.64×
-0.03×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons